Southern Medical Univ. EGFR compound 3a

Southern Medical Univ. EGFR compound 3a: sourced facts only. name: "In conclusion, compound 3a is a promising candidate for novel EGFR inhibitors targeting GBM." [PMID:39476599]; target: "In conclusion, compound 3a is a promising candidate for novel EGFR inhibitors targeting GBM." [PMID:39476599]; developer: "NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515 China." [PMID:39476599]; stage: "Compound 3a, which inhibited the growth of glioblastoma cell lines U87MG and U87-EGFRVIII, had average IC50 values of 4.69 µM and 4.98 µM, respectively." [PMID:39476599]